[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Shoji S, Shima M, Usui Y, Nagata Y, Uchida T, Terachi T: [A case report: simultaneous bilateral testicular tumors with different cell types--complete response after combination chemotherapy of cisplatin and irrinotecan hydrochloride--]. Hinyokika Kiyo; 2006 Apr;52(4):303-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report: simultaneous bilateral testicular tumors with different cell types--complete response after combination chemotherapy of cisplatin and irrinotecan hydrochloride--].
  • On examination, the patient was found to have bilateral testicular tumors with jugular chain lymph node and para-aortic lymph node metastasis.
  • Histopathological examination of the excised tumors revealed seminoma, embryonal carcinoma, yolk sac tumor and immature teratoma in the right testis and seminoma in the left testis.
  • The patient was treated postoperatively with two courses of BEP (bleomycin, etoposide, cisplatin) therapy and two courses of EP (etoposide, cisplatinum) therapy.
  • The patient had lung metastasis during the follow-up period and we treated him with salvage combination chemotherapy of cisplatin and irinotecan hydrochloride (CPT-11).
  • After the third course of cisplatin and CPT-11 chemotherapy the lung metastasis disappeared and we performed retroperitoneal lymph node dissection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endodermal Sinus Tumor / drug therapy. Neoplasms, Multiple Primary. Salvage Therapy. Seminoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Humans. Lung Neoplasms / secondary. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Remission Induction

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686361.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


2. Kuroda I, Ueno M, Mitsuhashi T, Nakagawa K, Yanaihara H, Tsukamoto T, Deguchi N: Testicular seminoma after the complete remission of extragonadal yolk sac tumor : a case report. BMC Urol; 2004 Nov 16;4:13
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular seminoma after the complete remission of extragonadal yolk sac tumor : a case report.
  • Of extragonadal germ cell tumors, testicular carcinoma in situ (CIS) are present in 31-42% of cases, and CIS are reported to have low sensitivity to chemotherapy in spite of the various morphology and to have a high likelihood of developing into testicular tumors.
  • A testicular biopsy may thus be highly advisable when evaluating an extragonadal germ cell tumor.
  • CASE PRESENTATION: A 36-year-old man was diagnosed as having an extragonadal non-seminomatous germ cell tumor, that was treated by cisplatin-based chemotherapy, leading to a complete remission.
  • In the meantime, testicular tumors were not detected by means of ultrasonography.
  • About 4 years later, a right testicular tumor was found, and orchiectomy was carried out.
  • Microscopically, the tumor was composed of seminoma.
  • CONCLUSIONS: We herein report a case of metachronous occurrence of an extragonadal and gonadal germ cell tumor.
  • In the evaluation of an extragonadal germ cell tumor, a histological examination should be included since ultrasonography is not sufficient to detect CIS or minute lesions of the testis.
  • [MeSH-major] Endodermal Sinus Tumor / drug therapy. Neoplasms, Second Primary / etiology. Seminoma / etiology. Testicular Neoplasms / drug therapy. Testicular Neoplasms / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Orchiectomy. Remission Induction

  • Genetic Alliance. consumer health - Seminoma.
  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1978 May;2(3):157-70 [27442.001]
  • [Cites] Ann Oncol. 2003 Sep;14(9):1412-8 [12954581.001]
  • [Cites] Hinyokika Kiyo. 2003 May;49(5):291-5 [12822460.001]
  • [Cites] APMIS. 2003 Jan;111(1):49-59; discussion 59-63 [12752235.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):121-4 [11863093.001]
  • [Cites] J Urol. 1989 Aug;142(2 Pt 1):243-7 [2545927.001]
  • [Cites] Urology. 1990 Aug;36(2):181-2 [2385889.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1995 Sep;86(9):1497-500 [7474641.001]
  • [Cites] J Urol. 1995 Oct;154(4):1367-9 [7658540.001]
  • [Cites] Lancet. 1994 May 7;343(8906):1130-2 [7910232.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1542-4 [8137260.001]
  • [Cites] Eur Urol. 1993;23(1):115-8; discussion 119 [8477771.001]
  • [Cites] Eur Urol. 1993;23(1):104-10; discussion 111-4 [8477770.001]
  • [Cites] Ann Oncol. 1992 Apr;3(4):283-9 [1327076.001]
  • [Cites] Urol Int. 1992;48(2):162-6 [1374974.001]
  • [Cites] Br J Cancer. 1998;77(2):329-35 [9461006.001]
  • (PMID = 15546481.001).
  • [ISSN] 1471-2490
  • [Journal-full-title] BMC urology
  • [ISO-abbreviation] BMC Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC535804
  •  go-up   go-down


3. Ross JH, Kay R: Prepubertal testis tumors. Rev Urol; 2004;6(1):11-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prepubertal testis tumors.
  • Because prepubertal testis tumors are rare, their management has historically been based on experience with the more common adult testis tumors.
  • However, recent studies highlighting the natural history of these tumors and their response to therapy have resulted in a modern management algorithm that optimizes testicular preservation and minimizes the morbidity of adjuvant therapies.
  • Many prepubertal testis tumors are benign and can be managed with testis-sparing tumor excision.
  • Localized malignant tumors (yolk sac tumors) may be managed with excision alone.
  • Recurrent tumors and metastatic disease can almost always be treated successfully with platinum-based chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1999 Jun;34(6):1000-3 [10392922.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):709-21 [9630178.001]
  • [Cites] Klin Padiatr. 1999 Jul-Aug;211(4):300-4 [10472566.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3809-18 [11078494.001]
  • [Cites] J Urol. 2001 Dec;166(6):2338-40 [11696779.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 2):1675-8; discussion 1678-9 [12352332.001]
  • [Cites] Crit Rev Oncol Hematol. 1990;10(2):99-110 [2163259.001]
  • [Cites] Br J Urol. 1990 Dec;66(6):648-51 [2265338.001]
  • [Cites] J Urol. 1990 Sep;144(3):726-30 [2388338.001]
  • [Cites] J Pediatr Surg. 1989 Jul;24(7):677-81; discussion 682 [2547053.001]
  • [Cites] Am J Surg Pathol. 1985 Oct;9(10):737-43 [4061731.001]
  • [Cites] J Urol. 1978 Jul;120(1):96-102 [566802.001]
  • [Cites] Cancer. 1980 Sep 15;46(6):1339-44 [6158370.001]
  • [Cites] Eur Urol. 1984;10(2):73-85 [6368238.001]
  • [Cites] J Urol. 1981 Nov;126(5):663-4 [7299932.001]
  • [Cites] Am J Clin Pathol. 1980 Nov;74(5):607-19 [7446466.001]
  • [Cites] Am J Surg Pathol. 1994 Sep;18(9):947-52 [7741838.001]
  • [Cites] J Urol. 1995 Apr;153(4):1259-61 [7869524.001]
  • [Cites] J Formos Med Assoc. 1994 May;93(5):393-6 [7920078.001]
  • [Cites] J Urol. 1994 Oct;152(4):1246-8 [8072115.001]
  • [Cites] Med Pediatr Oncol. 1994;22(5):329-40 [8127257.001]
  • [Cites] J Urol. 1994 Mar;151(3):715-7 [8308995.001]
  • [Cites] J Urol. 1993 Feb;149(2):353-6 [8426417.001]
  • [Cites] Urol Clin North Am. 1993 Feb;20(1):15-26 [8434434.001]
  • [Cites] Urol Clin North Am. 1993 Feb;20(1):27-37 [8434437.001]
  • [Cites] J Urol. 1997 Aug;158(2):608-9 [9224377.001]
  • [Cites] J Urol. 1997 Sep;158(3 Pt 2):1191-2 [9258169.001]
  • [Cites] Aust N Z J Surg. 1999 Jul;69(7):505-8 [10442922.001]
  • (PMID = 16985566.001).
  • [ISSN] 1523-6161
  • [Journal-full-title] Reviews in urology
  • [ISO-abbreviation] Rev Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1472674
  •  go-up   go-down


Advertisement
4. Kita M, Sasaki Y, Okuyama M, Saga Y, Hashimoto H, Kaneko S, Yachiku S, Tokumitsu M, Inada F, Ishida H: [Pulmonary rhabdomyosarcoma generated during treatment of testicular tumor]. Nihon Hinyokika Gakkai Zasshi; 2003 Nov;94(7):696-700
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary rhabdomyosarcoma generated during treatment of testicular tumor].
  • He had undergone right high orchiectomy, chemotherapy with four courses of PEB regimen (cisplatin, etoposide, bleomycin) and retroperitoneal lymph node dissection the previous year.
  • The pathological findings showed mixed germ cell tumor (seminoma, yolk sac tumor, embryonal carcinoma) in the testis and mature teratoma in the draining lymph node.
  • Two courses of salvage chemotherapy using a VIP regimen (etoposide, ifosfamide, cisplatin) were performed after diagnosis of pulmonary metastases, but had no affect on tumor size.
  • Video-assisted excision of pulmonary metastases was then performed, giving a pathological diagnosis of rhabdomyosarcoma in all three resected tumors.
  • The operation was followed by three courses of CYVADIC (cyclophosphamide, vincristine, adriamycin, dacarbazin) chemotherapy and oral cyclophosphamide, as a small residual tumor was suspected.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / secondary. Rhabdomyosarcoma / secondary. Testicular Neoplasms / therapy
  • [MeSH-minor] Adult. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / therapy. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Lymph Node Excision. Male. Orchiectomy. Pneumonectomy. Seminoma / pathology. Seminoma / therapy. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14672002.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; CYVADIC protocol; ICE protocol 1
  • [Number-of-references] 15
  •  go-up   go-down


5. Grady RW: Current management of prepubertal yolk sac tumors of the testis. Urol Clin North Am; 2000 Aug;27(3):503-8, ix
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of prepubertal yolk sac tumors of the testis.
  • Over the last 3 decades, the management of pediatric yolk sac tumors of the testis has changed significantly.
  • These changes reflect improvement in the treatment of testicular tumors in adults and children, such as the advent of platinum-based chemotherapy regimens.
  • They also reflect increased understanding of the biology and natural history of prepubertal yolk sac tumors of the testis as a unique disease entity.
  • [MeSH-major] Endodermal Sinus Tumor / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Humans. Lymph Node Excision. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10985149.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 29
  •  go-up   go-down


6. Kitahara K, Hori J, Tokumitsu M, Saga Y, Hashimoto H, Kaneko S, Yachiku S: [Retroperitoneal germ cell tumor with testicular calcification indicating tiny testicular origin: consideration of the origin of retroperitoneal germ cell tumors: report of two cases]. Hinyokika Kiyo; 2003 May;49(5):291-5
MedlinePlus Health Information. consumer health - Testicular Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retroperitoneal germ cell tumor with testicular calcification indicating tiny testicular origin: consideration of the origin of retroperitoneal germ cell tumors: report of two cases].
  • Two cases of germ cell neoplasm retrospectively considered to have been of testicular origin are reported. Case 1.
  • A 19-year-old male with brain, liver and retroperitoneal tumors was diagnosed with yolk sac tumor by retroperitoneal tumor biopsy.
  • After multidisciplinary treatment, a region of calcification was detected in the left testis on scrotal sonography and left high inguinal orchiectomy was performed. Case 2.
  • A 57-year-old male with neck, lung and retroperitoneal tumors was diagnosed with yolk sac tumor by supraclavicular biopsy.
  • From initial examination, scrotal sonography revealed a small calcified lesion in the right testis.
  • After chemotherapy, high inguinal orchiectomy and retroperitoneal lymphadenectomy were simultaneously performed.
  • Pathologic evaluation of these testicular specimens revealed calcification and a fibrous scar in correspondence with the clinical diagnosis.
  • These changes were considered as scars of the primary testicular tumor due to burned-out tumor or the result of reaction to chemotherapy.
  • Since a primary tumor of testicular origin may exist in the extragonadal germ cell tumor, it is important to examine the intrascrotal contents in detail in the case of so-called extragonadal germ cell tumors with palpably normal testes.
  • In such cases, there are two possible conditions, an occult testicular tumor and a burned-out testicular tumor.
  • It appears that there are very few true extragonadal germ cell tumors, and that the possibility of primary testicular origin metastasizing from viable occult testicular tumor or burned-out testicular tumor with spontaneous regression is high in retroperitoneal germ cell tumors.
  • [MeSH-major] Calcinosis / pathology. Germinoma / pathology. Retroperitoneal Neoplasms / pathology. Testicular Diseases / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Brain Neoplasms / pathology. Diagnosis, Differential. Endodermal Sinus Tumor. Humans. Liver Neoplasms / pathology. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12822460.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 15
  •  go-up   go-down


7. Lee JK, Kim SH, Kim JH, Kim IY, Kim TS, Jung S, Kang SS, Lee JH, Lee MC: Metastatic spinal cord compression of testicular yolk sac tumor. Childs Nerv Syst; 2002 Apr;18(3-4):171-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic spinal cord compression of testicular yolk sac tumor.
  • INTRODUCTION: Pediatric testicular tumors are rare.
  • Spinal metastasis of testicular yolk sac tumor (YST) is extremely rare, with only one reported case.
  • CASE REPORT: We report a rare case of metastatic spinal cord compression of testicular YST in a 14-month-old boy who presented with progressive paraparesis and neurological bladder dysfunction.
  • Two months prior to admission, he underwent a left radical orchiectomy for YST of the testis.
  • Emergency surgical resection was performed for tissue diagnosis and spinal decompression.
  • Histopathological features of the epidural mass indicated metastasis of the testicular YST.
  • CONCLUSION: Although spinal involvement with metastatic YST is rare, it must be considered in children with testicular YST exhibiting evidence of pain or weakness, and surgical decompression followed by adjuvant chemotherapy should not be delayed.
  • [MeSH-major] Endodermal Sinus Tumor / complications. Endodermal Sinus Tumor / secondary. Spinal Cord Compression / etiology. Spinal Neoplasms / complications. Spinal Neoplasms / secondary. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11981629.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F: Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin Cancer Res; 2009 May 15;15(10):3384-95
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
  • PURPOSE: Germ cell tumors (GCT) of the testis are highly curable, but those patients who are refractory to cisplatin (CDDP)-based combination chemotherapy have a poor prognosis.
  • Therefore, identifying new alternatives for treatment remains a priority.
  • Several studies support an important role for angiogenesis in GCTs, suggesting that antiangiogenic treatment might be a good alternative.
  • In the present study, we evaluated the effect of sunitinib, CDDP, or the combination of both drugs using an orthotopic model of human testicular GCT.
  • EXPERIMENTAL DESIGN: Mice were implanted with four different testicular tumors: a yolk sac, two choriocarcinomas, and a CDDP-resistant choriocarcinoma variant induced in mice by continuous exposure to CDDP.
  • Mice were treated with vehicle, CDDP, sunitinib, or the combination of both drugs and their effects on tumors were analyzed.
  • RESULTS: We observed a significant inhibition in tumor growth accompanied by longer survival after sunitinib treatment.
  • Combination therapy with CDDP significantly enhanced these effects.
  • Sunitinib induced apoptosis, reduced tumor cell proliferation and tumor vasculature, and inhibited vascular endothelial growth factor receptor 1, 2, and 3 and platelet-derived growth factor receptor alpha phosphorylation without affecting phosphorylation of other tyrosine kinase receptors.
  • More importantly, tumor growth inhibition induced by sunitinib was also observed in the induced CDDP-resistant choriocarcinoma model.
  • CONCLUSIONS: Taken together, these results suggest that sunitinib might be a new alternative for treatment of CDDP-refractory patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Indoles / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Pyrroles / therapeutic use. Testicular Neoplasms / drug therapy. Xenograft Model Antitumor Assays
  • [MeSH-minor] Angiogenesis Inhibitors / administration & dosage. Angiogenesis Inhibitors / pharmacology. Angiogenesis Inhibitors / therapeutic use. Animals. Apoptosis / drug effects. Blotting, Western. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Cisplatin / administration & dosage. Cisplatin / pharmacology. Drug Resistance, Neoplasm. Drug Synergism. Humans. Male. Mice. Mice, Nude. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / prevention & control. Receptors, Platelet-Derived Growth Factor / genetics. Receptors, Platelet-Derived Growth Factor / metabolism. Receptors, Vascular Endothelial Growth Factor / genetics. Receptors, Vascular Endothelial Growth Factor / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417025.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Miller KD, Michael H, Jacobson L, Sutton GP: Primary yolk sac tumor of the rectum. Cancer Invest; 2000;18(7):597-601
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary yolk sac tumor of the rectum.
  • Reports have primarily focused on the pediatric population and have suggested a poor prognosis for extragonadal yolk sac tumors.
  • A 23-year-old woman with a yolk sac tumor arising in the rectum is described.
  • Treatment with four courses of cisplatin, etoposide, and bleomycin was followed by surgical resection of the involved area.
  • No residual tumor was identified.
  • Previous reports are limited by the small number of patients, focus on the pediatric population, and treatment before the availability of cisplatin.
  • Extragonadal germ cell tumors in women are extremely rare but can be successfully treated with aggressive chemotherapy and surgery similar to testis cancer.
  • [MeSH-major] Endodermal Sinus Tumor / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11036466.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


10. Dede M, Pabuccu R, Yagci G, Yenen MC, Goktolga U, Gunhan O: Extragonadal yolk sac tumor in pelvic localization. A case report and literature review. Gynecol Oncol; 2004 Mar;92(3):989-91
Genetic Alliance. consumer health - Yolk sac tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extragonadal yolk sac tumor in pelvic localization. A case report and literature review.
  • BACKGROUND: Yolk sac tumor (YST) is a rare neoplasm that usually arises in the testis or ovary.
  • We report a case of extragonadal yolk sac tumor located in the pelvic area.
  • Histological evaluation of the specimen exhibited typical patterns of endodermal sinus tumor and stained for a-fetoprotein and cytokeratin.
  • Four courses of bleomycin, etoposide, and cisplatin combination chemotherapy repeated every 3 weeks were added to therapy and she has remained free of disease for 6 months after completion of the therapy.
  • [MeSH-major] Endodermal Sinus Tumor / pathology. Pelvic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14984973.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


11. Han G, Miura K, Takayama T, Tsutsui Y: Primary prostatic endodermal sinus tumor (yolk sac tumor) combined with a small focal seminoma. Am J Surg Pathol; 2003 Apr;27(4):554-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary prostatic endodermal sinus tumor (yolk sac tumor) combined with a small focal seminoma.
  • We report on a primary endodermal sinus tumor (EST) (yolk sac tumor) combined with a focal seminoma of the prostate occurring in a 24-year-old man.
  • Most areas of the tumor were composed of papillary and glandular epithelium in the fibrous or myxoid stroma.
  • In addition to yolk sac tumor, solid nests of seminoma were found in some areas.
  • Tumor cells exhibited negative staining for prostate-specific antigen, prostatic acid phosphatase, carcinoembryonic antigen, vimentin, chromogranin A, and human chorionic gonadotropin.
  • Despite radical surgery and ordinary cisplatin-based chemotherapy, the patient died 8 months after operation.
  • At autopsy, only EST elements had metastasized to the lungs, liver, and brain, and no tumors were found in either testis.
  • [MeSH-major] Endodermal Sinus Tumor / pathology. Neoplasms, Multiple Primary / pathology. Prostatic Neoplasms / pathology. Seminoma / pathology. Testicular Neoplasms / pathology


12. Guzel A, Tatli M, Belen D, Seckin H: Spinal cord compression of primary extragonadal giant yolk sac tumor. Spinal Cord; 2007 Mar;45(3):254-7
Genetic Alliance. consumer health - Yolk sac tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord compression of primary extragonadal giant yolk sac tumor.
  • OBJECTIVE: To report an adult male patient with a primary extragonadal giant yolk sac tumor presenting with acute spinal cord compression.
  • METHOD: A 31-year-old man was referred to our department with a diagnosis of Pott's disease, a complaint of back pain and gait difficulty for 2 weeks.
  • Abdominal computed tomography and lumbar magnetic resonance imaging study revealed a giant cystic mass lesion located in the psoas muscle.
  • Posteriorly, the third lumbar vertebral body was destructed and the tumor was compressing the dural sac.
  • Pathological diagnosis was a yolk sac tumor.
  • A chemotherapy protocol was given including bleomycin, etoposide and cisplatin.
  • Five months after the last chemotherapy, he was brought to the emergency unit in sepsis and died despite antibiotherapy.
  • CONCLUSION: Yolk sac tumor should be considered in young adult male patients presenting with acute paraparesis even without any signs or medical history of a testis tumor.
  • [MeSH-major] Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / surgery. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / surgery. Spinal Cord Compression / surgery
  • [MeSH-minor] Adult. Decompression, Surgical. Humans. Lumbosacral Region / pathology. Lumbosacral Region / surgery. Magnetic Resonance Imaging. Male. Paraparesis / etiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733519.001).
  • [ISSN] 1362-4393
  • [Journal-full-title] Spinal cord
  • [ISO-abbreviation] Spinal Cord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Hirayama Y, Kubota M, Imamura M, Imai C, Okuyama N, Tsukada M, Kobayashi K, Sato K, Takachi T, Iwavuchi H, Uchiyama M: A 2-year-old boy with a stage III yolk sac tumor occurring in an intra-abdominal retained testis. J Pediatr Surg; 2009 Dec;44(12):2395-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 2-year-old boy with a stage III yolk sac tumor occurring in an intra-abdominal retained testis.
  • We, herein, report the case of a 2-year-old boy who presented with a huge yolk sac tumor with retroperitoneal lymph nodes metastasis that originated in a left intra-abdominal undescended testis.
  • Computed tomography and magnetic resonance imaging showed a huge round tumor connecting to the left retroperitoneal lymph nodes with metastasis extending from the left pelvic region to the left renal hilum.
  • The right abdominal tumor appeared to be a giant testis that had strangulated at the neck of the cord.
  • The tumor had ruptured at the side of the left pelvic lymph node metastasis, and a yolk sac tumor was diagnosed from a histologic analysis of the resected specimens.
  • Postoperative PEB chemotherapy was effective, and a complete surgical resection of the tumor was performed 3 months after the initial laparotomy.
  • The pathologic findings showed fibrous tissue without any tumor cells.
  • This case might be a coincidental association of a yolk sac tumor occurring in an undescended testis, which thus caused a delay in making an accurate diagnosis.
  • [MeSH-major] Cryptorchidism / diagnosis. Endodermal Sinus Tumor / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] CA-125 Antigen / blood. Child, Preschool. Humans. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Male. Neoplasm Staging. Preoperative Care. Retroperitoneal Neoplasms / secondary. Testis / pathology. Testis / surgery. Tomography, X-Ray Computed. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20006035.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / alpha-Fetoproteins
  •  go-up   go-down


14. Tangour-Bouaicha M, Bel Haj Salah M, Ben Brahim E, Ben Othmène M, Douggaz A, Sassi S, Chatti-Dey S: [Primary peritoneal yolk sac tumour. A case report]. Ann Pathol; 2010 Oct;30(5):378-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary peritoneal yolk sac tumour. A case report].
  • [Transliterated title] Tumeur vitelline péritonéale primitive. À propos d'une observation.
  • Yolk sac tumours are rare germinal neoplasms that often arise in ovary and testis.
  • Microscopic examination of the pathologic specimen concluded to a yolk sac tumour.
  • Patient underwent intensive chemotherapy; she's free of disease 2 years after diagnosis.
  • Through this case, clinicopathologic features of this rare neoplasm will be discussed.
  • [MeSH-major] Endodermal Sinus Tumor / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Masson SAS.
  • (PMID = 21055525.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


15. Ross JH, Rybicki L, Kay R: Clinical behavior and a contemporary management algorithm for prepubertal testis tumors: a summary of the Prepubertal Testis Tumor Registry. J Urol; 2002 Oct;168(4 Pt 2):1675-8; discussion 1678-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical behavior and a contemporary management algorithm for prepubertal testis tumors: a summary of the Prepubertal Testis Tumor Registry.
  • PURPOSE: The Prepubertal Testis Tumor Registry was established by the Urologic Section of the American Academy of Pediatrics in 1980 to record data on a large number of prepubertal testis tumors regarding presentation, treatment and outcome to define appropriate management better.
  • MATERIALS AND METHODS: Relevant data in the prepubertal testis tumor registry were tabulated and analyzed.
  • RESULTS: There were 395 prepubertal patients who had a primary testis tumor.
  • Of the patients with yolk sac tumor 80% presented with stage 1 disease and overall survival was excellent.
  • Of all patients with stromal tumors metastases developed in only 1.
  • CONCLUSIONS: We recommend initial excisional biopsy for all amenable prepubertal testis tumors, except those with an alpha-fetoprotein level that is clearly increased for patient age.
  • Patients with stage I yolk sac tumor should be monitored closely, and those with recurrent or metastatic yolk sac tumor should be treated with chemotherapy.
  • Retroperitoneal lymph node dissection is reserved for patients with recurrent retroperitoneal masses following chemotherapy.
  • Aggressive treatment of metastatic Sertoli cell or undifferentiated stromal tumors is warranted.
  • [MeSH-major] Registries / statistics & numerical data. Testicular Neoplasms / congenital
  • [MeSH-minor] Algorithms. Child. Child, Preschool. Combined Modality Therapy. Endodermal Sinus Tumor / congenital. Endodermal Sinus Tumor / mortality. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Humans. Infant. Male. Neoplasm Staging. Prognosis. Sertoli Cell Tumor / congenital. Sertoli Cell Tumor / mortality. Sertoli Cell Tumor / pathology. Sertoli Cell Tumor / therapy. Sex Cord-Gonadal Stromal Tumors / congenital. Sex Cord-Gonadal Stromal Tumors / mortality. Sex Cord-Gonadal Stromal Tumors / pathology. Sex Cord-Gonadal Stromal Tumors / therapy. Survival Rate. United States. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12352332.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


16. Ye YL, Qin ZK, Zhou FJ, Han H, Liu ZW, Yu SL, Li YH, Chen ZF: [Clinical analysis of stage I pediatric testicular yolk sac tumors: a report of ten cases]. Ai Zheng; 2008 Nov;27(11):1226-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of stage I pediatric testicular yolk sac tumors: a report of ten cases].
  • BACKGROUND & OBJECTIVE: At present, pediatric testicular yolk sac tumor is hard to be diagnosed at early stage, and the treatment strategy for this disease after radical inguinal orchiectomy is uncertain.
  • This study was to summarize our experience in diagnosing and treating clinical stage I pediatric testicular yolk sac tumors.
  • METHODS: Clinical data of ten patients with clinical stage I pediatric testicular yolk sac tumors treated from July 2001 to June 2007 were analyzed.
  • RESULTS: Testicular masses with low or uneven echoes were detected by B ultrasound in 11 testes of ten patients.
  • Radical inguinal orchiectomy (RIO) was performed for all patients whereas chemotherapy was not administered preoperatively.
  • Pathology examination was used to confirm the diagnosis of yolk sac tumor.
  • One patient with vascular invasion and another one with bilateral testicular yolk sac tumor received cisplatin-based adjuvant chemotherapy.
  • The patient with bilateral testicular tumor had retroperitoneal and lung metastases at 23 months after adjuvant chemotherapy, and achieved complete remission again after salvage chemotherapy.
  • CONCLUSIONS: With the combination of B ultrasound and serum AFP level, we can assess and diagnose stage I pediatric testicular yolk sac tumor.
  • Chemotherapy is recommended to treat patients with high-risk of relapse.
  • [MeSH-major] Endodermal Sinus Tumor. Testicular Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Chemotherapy, Adjuvant. Child, Preschool. Cisplatin / therapeutic use. Etoposide / therapeutic use. Follow-Up Studies. Humans. Infant. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Neoplasm Staging. Orchiectomy / methods. Remission Induction. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / secondary. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19000459.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


17. Emerson RE, Ulbright TM: Intratubular germ cell neoplasia of the testis and its associated cancers: the use of novel biomarkers. Pathology; 2010 Jun;42(4):344-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratubular germ cell neoplasia of the testis and its associated cancers: the use of novel biomarkers.
  • Recent advances in the understanding of the molecular pathology of testicular tumours have led to the identification of several new immunohistochemical markers for invasive and in situ germ cell neoplasms.
  • A potential pitfall in their application to the detection of intratubular germ cell neoplasia, as in other markers that represent oncofetal antigens, is their expression in non-neoplastic germ cells with 'delayed maturation'.
  • SALL4, another nuclear stain, is positive for most germ cell tumours as a group and may be especially helpful in the distinction of these tumours from somatic carcinomas in non-testicular sites.
  • Glypican 3 is a more sensitive marker for yolk sac tumour than alpha-fetoprotein.
  • SOX2 and SOX17 may be useful for differentiating seminoma and embryonal carcinoma, especially following chemotherapy as embryonal carcinoma may lose CD30 expression in this setting.
  • This article reviews the application of these immunohistochemical markers and others to the diagnosis of germ cell neoplasia with reference to older immunohistochemical stains when appropriate.
  • Suggested immunohistochemical panels are described for individual tumour types.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasms, Germ Cell and Embryonal / metabolism. Testicular Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438407.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 96
  •  go-up   go-down


18. Terenziani M, Piva L, Spreafico F, Salvioni R, Massimino M, Luksch R, Cefalo G, Casanova M, Ferrari A, Polastri D, Mazza E, Bellani FF, Nicolai N: Clinical stage I nonseminomatous germ cell tumors of the testis in childhood and adolescence: an analysis of 31 cases. J Pediatr Hematol Oncol; 2002 Aug-Sep;24(6):454-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical stage I nonseminomatous germ cell tumors of the testis in childhood and adolescence: an analysis of 31 cases.
  • A 20-year single-institution experience of clinical stage I nonseminomatous germ cell tumors of the testis (NSGCTT) in childhood and adolescents was reviewed in relation to clinical characteristics, treatment modalities, and survival.
  • Yolk sac tumors and/or teratomas occurred in the children, whereas mixed histologies, including embryonal carcinoma, were predominant in the adolescents.
  • After orchiectomy, the children were assigned to surveillance and the adolescents to active treatment: 16 underwent retroperitoneal lymph node dissection (RPLND) and 1 had adjuvant cisplatin-based chemotherapy because of a high-risk histology.
  • Three of the 14 children (21.4%) relapsed 3, 7, and 8 months after orchiectomy: all 3 had yolk sac tumors and presented with increased alpha-fetoprotein levels.
  • All three children were treated with cisplatin-based chemotherapy with or without surgery.
  • All were treated with cisplatin-based chemotherapy with or without surgery.
  • In particular, almost all the childhood cases had the same yolk sac tumor histology, the children tended to have localized disease, and an increased alpha-fetoprotein level had a very high predictive value, suggesting that follow-up should include AFP measurements.
  • A conservative approach is the best option in children, while adolescent NSGCTT behaves like the adult disease and management must include similar treatment strategies.
  • [MeSH-major] Endodermal Sinus Tumor / pathology. Germinoma / pathology. Teratoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Cisplatin / therapeutic use. Combined Modality Therapy. Follow-Up Studies. Humans. Infant. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Staging. Orchiectomy. Retrospective Studies. Risk Factors. Survival Rate. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12218592.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Yang WP, Zou Y, Huang CS, Zhang SZ, Xiao Q, Dai KL, Zhong HS, Xiong XJ: [Clinicopathologic and prognostic study of pediatric immature teratoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Oct;36(10):666-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Amongst the 39 cases studied, 12 arose in the sacrococcygeal region, 12 in testis, 5 in retroperitoneum, 4 in ovary, 4 in abdomen and 2 in mediastinum.
  • Seven of the cases contained foci of yolk sac tumor.
  • Immature neuroepithelial features used in histologic grading included the presence of primitive neural tubules, immature rosettes, undifferentiated neuroblastoma cells and primitive neuroectodermal structures.
  • Three of them, including 2 cases with histologic grade 3 (with or without yolk sac tumor component), recurred after operation.
  • On the other hand, p27 overexpression shows little correlation with tumor grade.
  • Sacrococcygeal immature teratoma occurring in patients younger than 1 year old and with low histologic grade do not require postoperative chemotherapy if the tumor is completely excised.
  • Similarly, for testicular immature teratoma occurring in patients below 1 year of age, regardless of tumor grading, need no adjunctive therapy.
  • On the other hand, ovarian immature teratoma with high histologic grade requires postoperative chemotherapy, regardless of age of the patients.
  • The presence of microscopic foci of yolk sac tumor is a useful predictor of recurrence in pediatric immature teratoma.
  • [MeSH-major] Ovarian Neoplasms / pathology. Retroperitoneal Neoplasms / pathology. Teratoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Cyclin D1 / metabolism. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / metabolism. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / surgery. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Ki-67 Antigen / metabolism. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / metabolism. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Neoplasm Recurrence, Local. Neoplasm Staging. Proliferating Cell Nuclear Antigen / metabolism. Sacrococcygeal Region. Survival Rate. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18194599.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / alpha-Fetoproteins; 0 / p27 antigen; 136601-57-5 / Cyclin D1
  •  go-up   go-down


20. Sugiyama T, Hirano Y, Ushiyama T, Suzuki K, Fujita K, Ohmi Y: [Burned-out testicular tumor: a case report]. Hinyokika Kiyo; 2000 Nov;46(11):829-32
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Burned-out testicular tumor: a case report].
  • A small nodule was palpable in his left testis and ultrasonographic examination demonstrated that the nodule was low echoic.
  • Computed tomography showed a large mass in his left retroperitoneal space.
  • We thought the mass was a metastatic lesion from a testicular tumor.
  • Left orchiectomy was done and microscopic examination revealed no viable tumor cells.
  • Only fibrous tissue, small calcified areas, and hyaline bodies were found.
  • As tumor markers were normalized after 3 courses of chemotherapy with bleomycin, etoposide, and cisplatine, the retroperitoneal mass was removed with the left kidney.
  • It consisted of embryonal carcinoma, mature teratoma, and yolk sac tumor.
  • One course of adjuvant chemotherapy was done and the patient has since been free from recurrence.
  • We suppose that the tumor was a so-called 'burned-out' testicular tumor.
  • [MeSH-major] Carcinoma, Embryonal / secondary. Endodermal Sinus Tumor / secondary. Retroperitoneal Neoplasms / secondary. Teratoma / secondary. Testicular Neoplasms / diagnosis. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Neoplasms, Multiple Primary. Orchiectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11193307.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Wang WP, Guo C, Berney DM, Ulbright TM, Hansel DE, Shen R, Ali T, Epstein JI: Primary carcinoid tumors of the testis: a clinicopathologic study of 29 cases. Am J Surg Pathol; 2010 Apr;34(4):519-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoid tumors of the testis: a clinicopathologic study of 29 cases.
  • Testicular carcinoid tumors are rare with only limited studies.
  • We identified 29 primary testicular carcinoid cases from 7 academic institutions.
  • The most common presenting symptom was the sole finding of either a testicular mass or swelling seen in 15/24 cases with available information.
  • All 29 primary carcinoids lacked associated intratubular germ cell neoplasia, unclassified type.
  • Of the 28 cases found premortem, treatment included focal excision in 3 patients and radical orchiectomy in 25 patients.
  • Follow-up, available in 24 cases, ranged from 1 to 228 months (mean 52.7 mo); of the 20 patients with testicular typical carcinoid tumors found premortem, all were alive at last follow-up without recurrences or metastases.
  • Of the 4 patients with a primary atypical carcinoid tumor, 1 at the time of diagnosis had retroperitoneal and lung metastases who after chemotherapy underwent resection of the retroperitoneal tumor showing metastatic yolk sac tumor and embryonal carcinoma.
  • After resection, serum AFP levels remained elevated and the patient is scheduled for salvage chemotherapy and bone marrow transplant.
  • Most primary carcinoid tumors of the testis have a benign clinical course even if associated with epidermoid/dermoid cysts, or histologically mature teratoma.
  • [MeSH-major] Carcinoid Tumor / pathology. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Surg Pathol. 2010 Jul;34(7):1075. Ubright, Thomas M [corrected to Ulbright, Thomas M]
  • (PMID = 20351489.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


22. May M, Finkbeiner Y, Gunia S, Seehafer M, Knörig J, Hetzer R: Metastasizing testicular germ-cell tumor with infiltration of the right heart: indication for primary metastasectomy. Heart Vessels; 2006 Jan;21(1):63-5
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasizing testicular germ-cell tumor with infiltration of the right heart: indication for primary metastasectomy.
  • The case of a 42-year-old male patient with a testicular germ cell tumor extending into the superior caval vein, the left brachiocephalic vein, and the right heart, which manifested as a mild form of pulmonary embolization, is presented.
  • Due to the perceived high risk of continuous embolization and the urgent need to begin systemic chemotherapy, a complete cardiac tumor resection was performed, utilizing a cardiopulmonary bypass, followed by a simultaneous orchiectomy.
  • Histology revealed a 61-cm long vascular tumor as a metastasis of a yolk sac tumor originating from the left testis.
  • There were no postoperative complications, and the patient is alive and without tumor recurrence 12 months after four cycles of systemic chemotherapy according to the PEB (cisplatin, etoposide, bleomycin) scheme.
  • We conclude that in this special case aggressive surgical management following chemotherapy was very effective in controlling the disseminated testicular tumor.
  • [MeSH-major] Endodermal Sinus Tumor / secondary. Endodermal Sinus Tumor / surgery. Heart Neoplasms / secondary. Heart Neoplasms / surgery. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bleomycin / administration & dosage. Cardiopulmonary Bypass. Cisplatin / administration & dosage. Etoposide / administration & dosage. Heart Atria / pathology. Heart Ventricles / pathology. Humans. Male. Orchiectomy. Pulmonary Embolism / etiology. Treatment Outcome. Vena Cava, Superior / pathology

  • Genetic Alliance. consumer health - Heart tumor.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ind Med. 2004 Jan;45(1):24-33 [14691966.001]
  • [Cites] Ann Thorac Surg. 2002 May;73(5):1631-3 [12022566.001]
  • [Cites] Clin Cardiol. 1999 Jun;22(6):429-33 [10376186.001]
  • [Cites] J Urol. 1993 Jan;149(1):129-31 [8417194.001]
  • [Cites] Urology. 1995 Dec;46(6):883-7 [7502438.001]
  • [Cites] Heart Vessels. 2004 May;19(3):121-4 [15168059.001]
  • [Cites] Am J Cardiol. 1997 Sep 1;80(5):671-82 [9295010.001]
  • [Cites] Nihon Kyobu Geka Gakkai Zasshi. 1991 Oct;39(10):1966-70 [1960446.001]
  • (PMID = 16440152.001).
  • [ISSN] 0910-8327
  • [Journal-full-title] Heart and vessels
  • [ISO-abbreviation] Heart Vessels
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


23. Porcaro AB, Zecchini Antoniolli S, Novella G, Martignoni G, Bassetto MA, Poli A, Schiavone D, Tallarigo C, D'Amico A, Ficarra V, Curti P: [Histopathologic risk factors in patients with non-seminomatous germ tumors of the testis in clinical stage 1. Retrospective study of 75 patients]. Arch Ital Urol Androl; 2001 Dec;73(4):177-80
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histopathologic risk factors in patients with non-seminomatous germ tumors of the testis in clinical stage 1. Retrospective study of 75 patients].
  • [Transliterated title] Fattori istopatologici di rischio in pazienti con tumore germinale non seminomatoso del testicolo in stadio clinico 1. Uno studio retrospettivo su 75 pazienti.
  • OBJECTIVES: This retrospective study was performed to evaluate histopathologic prognostic risk factors in 75 patients on clinical stage 1 nonseminomatous germ cell cancer of the testis (NSGCTT).
  • After orchiectomy, therapeutic options included retroperitoneal lymph node dissection (RLND) for 44 patients (58.6%), surveillance for 26 (34.6%) and neoadjuvant chemotherapy for 5 (6.6%).
  • Testis primary tumor samples were assessed for studying prognostic risk factors that included vascular and/or lymphatic invasion (IV/IL+), percentage of embryonal carcinoma (%EC) and absence of yolk sac tumor (YS-).
  • CONCLUSIONS: EC% > 80 is a prognostic risk factor for disease relapse in patients with clinical stage 1 NSGCT who are selected in a high risk group requiring RPLND or neoadjuvant chemotherapy as therapeutical option.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11822063.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ITA
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Popadiuk S, Korzon M, Chybicka A, Szmyd K, Dzierzega M, Trelińska J, Kowalczyk JR, Wiśniewska-Slusarz H, Woźniak W, Bilska K, Wachowiak J, Konatkowska B, Wysocki M, Krawczuk-Rybak M, Czauderna P, Szumera M, Sznurkowska K, Renke J: [Testicular malignant tumours. Efficacy of germ cell and sex cord tumours treatment protocol in Poland]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):811-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular malignant tumours. Efficacy of germ cell and sex cord tumours treatment protocol in Poland].
  • Approximately 2% of of all malignant tumours in boys are localised in the testis.
  • Among them 80% are germ cell tumours with the malignant elements of yolk sac tumour.
  • AIM of the study was evaluation of the efficacy of malignant testicular tumour treatment programme in children.
  • MATERIAL AND METHODS: Since 1998 31 boys aged 1 month to 18 years (median 14 years) with malignant testicular tumours were enrolled in the multicentre trial.
  • Patomorphologically clear yolk sac tumour (33%) and mixed germ cell tumour (42%) with the majority of yolk sac tumour component or carcinoma embryonale, occurred most often.
  • 61% patients had local clinical stage and the tumour was localized in the testis.
  • In 39% patients tumour exceeded the testis margin.
  • 33% received no chemotherapy after surgery, in 41% VBP protocol (vinblastine, bleomycin, cisplatin) was given and in 26%o VIP protocol (ethoposide, ifosphamide, cisplatin).
  • RESULTS: Among 26 children with germ cell tumours, 25 (96%) are alive, 23 (88%) are in first remission after completion of treatment.
  • 2 children had local recurrence treated with chemotherapy or surgery with good result.
  • CONCLUSIONS: TGM regimen is highly efficient in the treatment of malignant testicular tumours.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Sex Cord-Gonadal Stromal Tumors / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Bleomycin / administration & dosage. Carboplatin / administration & dosage. Child. Child, Preschool. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Endodermal Sinus Tumor / drug therapy. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Poland. Remission Induction. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317912.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Poland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; COB protocol
  •  go-up   go-down


25. Tröbs RB, Krauss M, Geyer C, Tannapfel A, Körholz D, Hirsch W: Surgery in infants and children with testicular and paratesticular tumours: a single centre experience over a 25-year-period. Klin Padiatr; 2007 May-Jun;219(3):146-51
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery in infants and children with testicular and paratesticular tumours: a single centre experience over a 25-year-period.
  • Testicular and even more paratesticular tumours in children are rare.
  • The aim of the study is to characterise the spectrum of these lesions with focus on the feasibility and effectiveness of testis sparing surgery.
  • The spectrum of testicular tumours comprised 13 germ cell tumours (6 yolk sac tumours, 6 teratomas, 1 embryonal carcinoma) and 4 sex cord stromal tumours (2 Leydig's cell, Sertoli's cell, granulosa cell).
  • Further on, we observed 3 boys with paratesticular rhabdomyosarcoma (RMS), and three with testicular and paratesticular metastases (Wilms' tumour, neuroblastoma, leukaemia).
  • Serum alpha1-fetoprotein (AFP) was clearly elevated in 5 of 6 yolk sac tumours but remained within normal limits concerning the other entities.
  • Dependent on tumour histology, stage and the recommended treatment schedule postoperative chemotherapy was added.
  • Testis sparing surgery was performed in 3 boys with primary testicular tumours (2 Leydig's cell, mature cystic teratoma).
  • During a median follow up of 5 years all patients with primary testicular tumours survived event free.
  • Meta-analysis of the recent literature revealed that testis sparing surgery is feasible and save in prepubertal boys after exclusion of a malignant tumour.
  • If a testis sparing approach is planned, the following criteria are essential: 1.
  • 3. The presence of sufficient healthy testicular parenchyma.
  • However, the high rate of malignant or potentially malignant tumours suggests that high inguinal orchidectomy should remain the surgical standard of therapy.
  • [MeSH-major] Granulosa Cell Tumor / surgery. Leydig Cell Tumor / surgery. Neoplasms, Germ Cell and Embryonal / surgery. Sertoli Cell Tumor / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Diagnostic Imaging. Feasibility Studies. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Orchiectomy / methods. Retrospective Studies. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525908.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


26. Mikuz G: [Testicular tumors. Predictive factors]. Pathologe; 2008 Nov;29 Suppl 2:270-2
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular tumors. Predictive factors].
  • Patients with germ cell tumors of the testis can be given adjuvant treatment immediately after orchidectomy or put under surveillance with definitive treatment deferred until relapse.
  • Both therapies are equally successful (success rate 98-99%), with surveillance alone, however, only approximately 50% of cases need toxic chemotherapy.
  • In seminomas the strongest predictor of metastases is tumor invasion of the rete testis followed by the size (Ø > or =4 cm) of the tumor.
  • The presence of teratomas and yolk sac tumors are considered to be predictors of a favorable course of the disease.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Follow-Up Studies. Humans. Male. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / pathology. Orchiectomy. Prognosis. Testis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ital Urol Androl. 2001 Dec;73(4):177-80 [11822063.001]
  • [Cites] Eur Urol. 2008 Mar;53(3):478-96 [18191324.001]
  • [Cites] Lancet. 1987 Aug 8;2(8554):294-8 [2886764.001]
  • [Cites] Urologe A. 1999 Mar;38(2):168-78 [10231939.001]
  • [Cites] Urology. 2007 Oct;70(4):777-80 [17991554.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8717-23 [16260698.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5482-92 [17158533.001]
  • [Cites] Eur J Cancer. 2002 Oct;38(15):2014-9 [12376206.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):736-40 [15708251.001]
  • [Cites] J Urol. 1998 Jan;159(1):133-8 [9400455.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4448-52 [12431967.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):576-82 [11290432.001]
  • (PMID = 18712393.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Chen YS, Kuo JY, Chin TW, Wei CF, Chen KK, Lin AT, Chang LS: Prepubertal testicular germ cell tumors: 25-year experience in Taipei Veterans General Hospital. J Chin Med Assoc; 2008 Jul;71(7):357-61
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prepubertal testicular germ cell tumors: 25-year experience in Taipei Veterans General Hospital.
  • BACKGROUND: Due to the rarity of testicular tumors in the prepubertal population, adequate information about their biological course is difficult to document well in a single institution.
  • The purpose of this study was to focus on prepubertal males in an attempt to evaluate clinical features and optimal management among various testicular germ cell tumors with long-term follow-up.
  • METHODS: We retrospectively reviewed the records of children younger than 12 years of age with primary testicular germ cell tumors between February 1981 and December 2005 at Taipei Veterans General Hospital.
  • Mean follow-up time was 139 months (range, 2-283 months).
  • The mean age of the patients at diagnosis ranged from 6 months to 84 months (mean, 20.5 months).
  • All patients underwent radical orchiectomy as an initial treatment.
  • Twenty-nine (85.3%) patients had yolk sac tumors, and 5 (14.7%) had mature teratomas.
  • Of the 29 patients with yolk sac tumor, 26 (89.7%) were diagnosed as stage I, 1 (3.4%) as stage III, and 2 (7.0%) as stage IV.
  • Five (19.2%) of the 26 stage I yolk sac tumors progressed to metastasis after radical orchiectomy, and all of these 5 patients later received chemotherapy.
  • One patient initially with stage III yolk sac tumor and 2 patients with stage IV yolk sac tumor were also treated with chemotherapy.
  • Eventually, 1 patient with stage IV yolk sac tumor died due to tumor progression; the remaining 28 patients with yolk sac tumor all survived without tumor relapse after appropriate treatment.
  • In the 5 patients with teratomas, there was no tumor relapse after radical orchiectomy with a mean follow-up time of 139.1 months.
  • The 5-year survival rates for yolk sac tumor and teratomas were 96.5% and 100%, respectively.
  • CONCLUSION: The most common prepubertal malignant testicular tumor is yolk sac tumor, and the most common benign testicular tumor is teratoma.
  • Children with testicular germ cell tumors have excellent long-term survival rates after appropriate treatment.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / therapy. Testicular Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18653399.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


28. De Backer A, Madern GC, Wolffenbuttel KP, Oosterhuis JW, Hakvoort-Cammel FG, Hazebroek FW: Testicular germ cell tumors in children: management and outcome in a series of 20 patients. J Pediatr Urol; 2006 Jun;2(3):197-201

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular germ cell tumors in children: management and outcome in a series of 20 patients.
  • Testicular germ cell tumors occurring during childhood are extremely rare.
  • This study reports the clinical presentation, pathological diagnosis, treatment methods and outcome in a series of 20 boys, aged between 3.5 months and 16 years (median: 1.5 years; 19 were prepubertal), who were treated between 1963 and 2003.
  • Histologically, mature teratoma was present in seven, immature teratoma in four and yolk sac tumor in nine.
  • Of the 11 teratomas, 10 were treated by orchiectomy and one by testis-sparing tumor excision only.
  • The nine patients with yolk sac tumor were managed by orchiectomy, in two plus retroperitoneal lymphadenectomy, and in eight plus chemotherapy.
  • One patient is in remission for 10 months, seven are alive with no evidence of disease for 5.5-23 years, and one patient died from a T-cell acute lymphoblastic leukemia, 2 years after the end of treatment of the testicular tumor.
  • A gradual switch towards less invasive treatment has been observed over the years.
  • This study confirms the excellent cure rates obtained in children with testicular germ cell tumor, provided diagnosis is prompt and treatment accurate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947609.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Mann JR, Gray ES, Thornton C, Raafat F, Robinson K, Collins GS, Gornall P, Huddart SN, Hale JP, Oakhill A, UK Children's Cancer Study Group Experience: Mature and immature extracranial teratomas in children: the UK Children's Cancer Study Group Experience. J Clin Oncol; 2008 Jul 20;26(21):3590-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature and immature extracranial teratomas in children: the UK Children's Cancer Study Group Experience.
  • PURPOSE: The purpose of this article is to describe the features, treatment, and risk factors for relapse of children with mature teratoma (MT) and immature teratoma (IT) to assist future treatment plans.
  • PATIENTS AND METHODS: Patients were younger than 16 years of age and referred to the UK Children's Cancer Study Group centers with biopsy-proven extracranial MT and IT and no prior chemotherapy.
  • Complete excision, with the coccyx in sacrococcygeal patients, and follow-up, including serum alpha-fetoprotein monitoring for early detection of malignant yolk sac tumor (YST) recurrence, were recommended.
  • Pathology was reviewed and treatments, outcome, and prognostic features assessed.
  • Tumor sites were: testis (n = 53), ovary (n = 130), sacrococcygeal region (n = 98), thorax (n = 23), and other (n = 47).
  • Poorer outcome occurred with incomplete resection, tumor rupture, nongonadal site (particularly sacrococcygeal), young age, higher stage and grade, and gliomatosis peritonei, but not with cyst fluid aspiration/spillage, tumor enucleation, nodal gliomatosis, or microfoci of YST in the tumor (Heifetz lesions).
  • CONCLUSION: Treatment remains primarily surgical, with JEB chemotherapy for YST relapse.
  • Adjuvant chemotherapy after surgery for sacrococcygeal patients is not advocated.
  • [MeSH-major] Neoplasm Recurrence, Local / epidemiology. Teratoma / pathology. Teratoma / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Disease-Free Survival. Female. Great Britain. Humans. Infant. Male. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541896.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


30. Carver BS, Bianco FJ Jr, Shayegan B, Vickers A, Motzer RJ, Bosl GJ, Sheinfeld J: Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J Urol; 2006 Jul;176(1):100-3; discussion 103-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
  • We evaluated patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell tumors to determine predictors of teratomatous elements in the retroperitoneum.
  • MATERIALS AND METHODS: We identified 532 patients from 1989 to 2003 who underwent retroperitoneal lymph node dissection following chemotherapy for nonseminomatous germ cell tumors at our institution.
  • RESULTS: Of the 532 patients in our series 450 (85%) received only induction chemotherapy and 82 (15%) required salvage chemotherapy.
  • By multivariate analysis testicular yolk sac tumor (p = 0.046), teratoma in the orchiectomy specimen (p <0.005), relative change in nodal size before and after chemotherapy (p <0.005), and no requirement for salvage chemotherapy (p = 0.03) were independent predictors for the presence of teratoma in the retroperitoneum.
  • CONCLUSIONS: Teratoma remains a common histological finding in the retroperitoneal lymph nodes following chemotherapy.
  • We have identified several pre-retroperitoneal lymph node dissection variables that predict the finding of teratoma in the retroperitoneum for men treated with chemotherapy for metastatic nonseminomatous germ cell tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymph Node Excision. Teratoma / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Humans. Logistic Models. Lymphatic Metastasis. Male. Multivariate Analysis. Retroperitoneal Space. Salvage Therapy

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753380.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


31. Antón L, Pérez-Etchepare E, Soriano D, Gómez M, Barrientos G, Tracchia R: [Testicular tumors: wide spectrum in our short casuistics]. Cir Pediatr; 2010 Oct;23(4):222-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular tumors: wide spectrum in our short casuistics].
  • Testicular tumors occur in 0.5 to 2 per 100,000 children.
  • The clinical history, testicular and abdominal ultrasonography, alpha-fetoprotein and human chorionic gonadotropin, estrogens and androgen levels, FSH and LH determine the diagnosis.
  • We report seven cases, three germ cell tumors: a Yolk sac tumor in a child of 18 months and two mature teratomas in children between 2 and 11 years presenting as a painless testicular mass without other symptoms.
  • Three tumors estrumales: one derived from Leydig cells and two of the granulosa cells, a palpable testicular mass was added precocious puberty in stage II-III of Tanner in the first, second gynecomastia in Tanner stage III and the third only with testicular mass.
  • The seventh case, Lipoma para-testicular mass palpable.
  • The treatment was radical orchiectomy in five cases.
  • Testis-sparing surgery in Leydig cell tumor and resection of the paratesticular mass was performed through scrotal.
  • The Yolk sac tumor requiring chemotherapy with good outcome.
  • Historically prepubertal testicular tumors have been treated in adults.
  • Recent testicular preservation algorithms optimize and minimize the morbidity of adjuvant therapies.
  • Many are benign and can be treated with preservation of the testis.
  • [MeSH-major] Testicular Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21520554.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


32. Mikuz G: [WHO classification of testicular tumors]. Verh Dtsch Ges Pathol; 2002;86:67-75
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [WHO classification of testicular tumors].
  • [Transliterated title] WHO-Klassifikation der Hodentumoren.
  • Twenty years after the first edition (1977), the WHO has presented the updated version of the "Histological typing of testis tumours".
  • Such atypical cells appear in the tubules adjacent to the germ cell tumors, in some few cases (6%) also in the contra lateral healthy gonad and rarely in infertile men (1%).
  • The precursor lesion can progress to franc germ cell tumor starting probably with seminoma, which still maintain the capability of differentiation (pluripotente cells) in all other types of non-seminomatous germ cell tumors.
  • This is a harmless name for an extremely dangerous tumor in which one tissue overgrows the other and gives rise to somatic type sarcomas or carcinomas.
  • Such tumors do not respond like germ cell tumors to the usual chemotherapy.
  • Treatment should be tailored according to that used in standard management of the respective sarcoma or carcinoma.
  • In the comments it is mentioned that the testis carcinoid could be a part of teratoma, but the diagnosis is listed in the group of "miscellaneous" tumors together with tumors of ovarian epithelial type.
  • This is a very questionable decision because the normal testis does not contain neuroendocrine cells from which carcinoids would have to be able to develop.
  • "Large cell calcifying Sertoli cell tumour" has been recently described and can be sporadic or inherited.
  • This morphologically peculiar tumor can be part of the Swiss syndrome also called Carney's complex.
  • The patients have cardiac myxomas, spotty skin pigmentation, hormone active nodular hyperplasia of the adrenals and soft tissue myxomas.
  • For the therapy of germ cell tumor an assessment of risk factors found by the pathologists is extremely important.
  • The most important independent predictors of relapse are tumor invasion of blood or lymph-vessels, absence of yolk sac elements and the presence of an embryonal carcinoma component.
  • In the absence of such predictors a surveillance policy allows some patients to forgo chemotherapy.
  • [MeSH-major] Testicular Neoplasms / classification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12647353.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


33. Subramanian VS, Gilligan T, Klein EA: A case of spermatic cord teratoma in low-stage testicular cancer managed by surveillance. Nat Clin Pract Urol; 2008 Apr;5(4):220-3
Genetic Alliance. consumer health - Testicular cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of spermatic cord teratoma in low-stage testicular cancer managed by surveillance.
  • BACKGROUND: A 25-year-old male presented to his local urologist with new-onset right testicular pain and swelling detected on self examination.
  • A scrotal ultrasound scan showed a right testicular mass, suspicious for neoplasm.
  • The patient underwent right inguinal orchiectomy and was diagnosed with nonseminomatous germ cell tumor of the right testis, composed of yolk sac tumor, teratoma, and embryonal carcinoma with no evidence of metastatic disease.
  • He opted to remain under surveillance rather than undergo primary chemotherapy or retroperitoneal lymph node dissection for his clinical stage I disease.
  • Serologic relapse at 4 months after orchiectomy was successfully treated with bleomycin, etoposide and cisplatin (BEP) chemotherapy.
  • Pathology of the testicular mass was reviewed.
  • DIAGNOSIS: A 1.7 cm nodule anterior to the right psoas muscle suspicious for metastatic disease that was seen on CT 16 months after orchiectomy was pathologically confirmed as recurrent mature teratoma in the spermatic cord.
  • The patient has since remained disease-free, with normal levels of serum tumor markers and no evidence of metastasis on chest X-ray and abdominal CT.
  • [MeSH-major] Genital Neoplasms, Male / therapy. Neoplasms, Germ Cell and Embryonal / surgery. Spermatic Cord / pathology. Teratoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin / blood. Disease Management. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local / therapy. Orchiectomy. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18268549.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / alpha-Fetoproteins
  •  go-up   go-down


34. Gyorffy H, Tihanyi T, Gyökeres T, Zsirka-Klein A, Kádár P, Kaszás I, Kovács M: [Pancreas pseudocyst or metastasis?]. Orv Hetil; 2005 Oct 23;146(43):2223-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumour, however, was found independent of the pancreas (90 x 80 x 50 mm).
  • Both histologically and immunohistochemically the lesion proved to be the metastasis of a germ cell (yolk-sac) tumour.
  • Following the morphological diagnosis, detailed urological and medical check up was performed.
  • A previously nonpalpable small tumour was found in the left testis which was radically resected.
  • The testicular tumour measuring 9 x 9 x 5 mm in diameter was diagnosed as embryonal carcinoma.
  • Later on the patient underwent chemotherapy.
  • The possibility of a metastasis, especially of germ cell origin, should be excluded (not only by physical examination, but by ultrasound of testis also) in case of retroperitoneal cystic tumours even with unusual morphology.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / secondary. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / secondary. Pancreatic Pseudocyst / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323569.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


35. Juric D, Sale S, Hromas RA, Yu R, Wang Y, Duran GE, Tibshirani R, Einhorn LH, Sikic BI: Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. Proc Natl Acad Sci U S A; 2005 Dec 6;102(49):17763-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Germ cell tumors (GCTs) of the testis are the predominant cancer among young men.
  • We identified 511 genes, belonging to several critical functional groups such as cell cycle progression, cell proliferation, and apoptosis, to be significantly differentially expressed in GCTs compared with other tumor types.
  • Sixty-five genes were sufficient for the construction of a GCT class predictor of high predictive accuracy (100% training set, 96% test set), which might be useful in the diagnosis of tumors of unknown primary origin.
  • Several additional differentially expressed genes were identified in teratomas (EGR1 and MMP7), yolk sac tumors (PTPN13 and FN1), and seminomas (NR6A1, DPPA4, and IRX1).
  • Dynamic computation of interaction networks and mapping to existing pathways knowledge databases revealed a potential role of EGR1 in p21-induced cell cycle arrest and intrinsic chemotherapy resistance of mature teratomas.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2359-64 [11956097.001]
  • [Cites] Genome Biol. 2005;6(3):R22 [15774023.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47861-9 [12354757.001]
  • [Cites] Mol Cancer Ther. 2002 Jun;1(8):639-49 [12479224.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):94-6 [12519956.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):219-23 [12519986.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):767-73 [12576448.001]
  • [Cites] Development. 2003 Apr;130(8):1673-80 [12620990.001]
  • [Cites] Oncogene. 2003 Mar 27;22(12):1880-91 [12660824.001]
  • [Cites] Dev Biol. 1999 Nov 15;215(2):399-406 [10545246.001]
  • [Cites] Acta Oncol. 2000;39(4):509-17 [11041114.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(2):663-77 [11134352.001]
  • [Cites] Gene. 2000 Dec 30;260(1-2):1-12 [11137286.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Development. 2001 Aug;128(15):2847-55 [11532909.001]
  • [Cites] FEBS Lett. 2001 Oct 19;507(1):59-66 [11682060.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8235-40 [11719455.001]
  • [Cites] J Pathol. 2002 Apr;196(4):423-9 [11920738.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4592-5 [11904381.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2244-50 [12727846.001]
  • [Cites] APMIS. 2003 Jan;111(1):136-50; discussion 50-1 [12752254.001]
  • [Cites] Bioinformatics. 2003 Jul 22;19(11):1325-32 [12874043.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13350-5 [14595015.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2368-78 [15073113.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14 [15184677.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1090-8 [15448693.001]
  • [Cites] Mol Endocrinol. 1994 Oct;8(10):1434-44 [7854358.001]
  • [Cites] Science. 1995 Apr 21;268(5209):411-5 [7536343.001]
  • [Cites] J Biol Chem. 1995 Dec 22;270(51):30303-9 [8530452.001]
  • [Cites] Cell Growth Differ. 1997 Mar;8(3):293-9 [9056671.001]
  • [Cites] Urology. 1997 Aug;50(2):302-7 [9255310.001]
  • [Cites] J Biol Chem. 1997 Sep 26;272(39):24333-8 [9305890.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Oncogene. 1999 Jun 17;18(24):3633-42 [10380885.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7 [10430922.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8521-30 [15623634.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):210-22 [15738984.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • (PMID = 16306258.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102283; United States / NCI NIH HHS / CA / R33 CA 89830; United States / NCI NIH HHS / CA / P01 CA 74295; United States / NCI NIH HHS / CA / R33 CA089830; United States / NCI NIH HHS / CA / R01 CA 102283
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1308932
  •  go-up   go-down


36. Berney DM, Shamash J, Gaffney J, Jordan S, Oliver RT: DNA topoisomerase I and II expression in drug resistant germ cell tumours. Br J Cancer; 2002 Sep 9;87(6):624-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA topoisomerase I and II expression in drug resistant germ cell tumours.
  • A small number of testicular germ cell tumours are refractory to current chemotherapy regimens.
  • DNA topoisomerase I is the target for several new drugs and a potential candidate treatment for chemorefractory germ cell tumours.
  • DNA topoisomerase II alpha is the target for etoposide, which is currently used regularly in germ cell tumour treatment.
  • The expression of DNA topoisomerase I and II alpha were therefore assessed immunohistochemically in a range of testicular tumours, especially those with persistent malignant elements on retroperitoneal lymph node dissection.
  • Pre-chemotherapy orchidectomy specimens were matched with post-chemotherapy retroperitoneal lymph node dissections to examine changes in expression.
  • There was considerable variation in the expression of topoisomerase I in different tumour types.
  • Both yolk sac tumours and teratoma, mature showed universal expression of topoisomerase I, while 38% of seminomas and 30% of embryonal carcinomas were positive.
  • There was a negative correlation between topoisomerase I and II alpha expression (P=0.004) and downregulation of topoisomerase II alpha after chemotherapy (P=0.02).
  • These results suggest that topoisomerase I inhibitors may be useful in chemorefractory germ cell tumours, especially yolk sac tumours and where there are unresectable residual teratoma, mature deposits.
  • [MeSH-major] Carcinoma, Embryonal / metabolism. DNA Topoisomerases, Type I / metabolism. DNA Topoisomerases, Type II / metabolism. Drug Resistance, Neoplasm. Seminoma / metabolism. Teratoma / metabolism. Testicular Neoplasms / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Cisplatin / administration & dosage. Down-Regulation. Etoposide / administration & dosage. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Testis / chemistry. Testis / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 2000 Mar;108(3):209-15 [10752690.001]
  • [Cites] Hum Pathol. 2000 Feb;31(2):214-9 [10685636.001]
  • [Cites] Hum Pathol. 2000 Jun;31(6):728-33 [10872667.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):787-95 [10879730.001]
  • [Cites] J Urol. 2000 Aug;164(2):381-4 [10893590.001]
  • [Cites] Brain Tumor Pathol. 2000;17(1):7-13 [10982004.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):340-3 [11161398.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2647-57 [11352956.001]
  • [Cites] Histopathology. 2001 Oct;39(4):382-5 [11683938.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):2925-32 [11712788.001]
  • [Cites] Cancer. 1981 Aug 15;48(4):904-8 [6168361.001]
  • [Cites] Br J Cancer. 1984 Nov;50(5):601-9 [6093838.001]
  • [Cites] N Engl J Med. 1987 Dec 3;317(23):1433-8 [2446132.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6919-24 [1698546.001]
  • [Cites] Cancer Res. 1992 Feb 1;52(3):525-32 [1310066.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1294-9 [8391067.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):120-6 [7505805.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):539-46 [8275492.001]
  • [Cites] J Urol. 1994 Oct;152(4):1144-9 [8072083.001]
  • [Cites] Int J Cancer. 1994 Dec 1;59(5):607-11 [7960233.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2129-34 [7743513.001]
  • [Cites] Br J Cancer. 1995 Dec;72(6):1454-61 [8519659.001]
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):2117-20 [8572612.001]
  • [Cites] J Cell Biol. 1996 Aug;134(3):757-70 [8707853.001]
  • [Cites] Annu Rev Biochem. 1996;65:635-92 [8811192.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Eur Urol. 1997;31(1):92-6 [9032542.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1425-8 [9108439.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 1;25(21):4181-6 [9336444.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5475-9 [9407953.001]
  • [Cites] Mol Pathol. 1997 Oct;50(5):247-53 [9497914.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2500-4 [9667270.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):107-19 [9748525.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):384-91 [10208458.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):685-92 [10442191.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4237-41 [10485464.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):313-9 [9602266.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):257-73 [10680894.001]
  • [Cites] Hum Pathol. 2000 Jun;31(6):631-2 [10872653.001]
  • (PMID = 12237772.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 6PLQ3CP4P3 / Etoposide; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.3 / DNA Topoisomerases, Type II; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2364243
  •  go-up   go-down


37. Steffens J, Treiyer A, Calaminus G: [Management of pediatric testicular tumors : diagnosis, therapy, and follow-up]. Urologe A; 2009 Apr;48(4):359-63
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of pediatric testicular tumors : diagnosis, therapy, and follow-up].
  • [Transliterated title] Präpubertäre Hodentumoren : Diagnose, Therapie und Nachbeobachtung.
  • Based on findings from the Prepubertal Testis Tumor Registry by the Urologic Section of the American Academy of Pediatrics and collaborative data in the literature, a modern algorithm for the surgical management of prepubertal testis tumors is presented.
  • Following testicular surgery, patients with universally benign tumors, such as teratoma, may be released from oncological follow-up.
  • Children with stage I yolk sac tumors should be monitored closely with periodic AFP tumor marker evaluation and imaging according to the primary dissemination (e.g., ultrasound, chest x-ray, and computed tomography).
  • Patients with recurrent or metastatic yolk sac tumors should be treated with platinum-based chemotherapy and appropriate follow-up.
  • Retroperitoneal lymph node dissection is not recommended except for patients with residual retroperitoneal masses following chemotherapy.
  • Aggressive treatment is warranted for metastatic Sertoli cell and metastatic undifferentiated stromal tumors.
  • [MeSH-major] Medical Oncology / trends. Pediatrics / trends. Testicular Neoplasms / diagnosis. Testicular Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Children's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2412-5; discussion 2415-6 [14634440.001]
  • [Cites] J Urol. 2004 Aug;172(2):674-8 [15247758.001]
  • [Cites] J Pediatr Urol. 2007 Dec;3(6):480-3 [18947799.001]
  • [Cites] Klin Padiatr. 2002 Jul-Aug;214(4):167-72 [12165897.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 2):1675-8; discussion 1678-9 [12352332.001]
  • [Cites] J Urol. 2004 Jan;171(1):161-3 [14665867.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 2):671-4 [8392120.001]
  • [Cites] J Urol. 2004 Dec;172(6 Pt 1):2370-2 [15538270.001]
  • [Cites] Klin Padiatr. 1999 Jul-Aug;211(4):300-4 [10472566.001]
  • [Cites] J Urol. 2008 May;179(5):1961-5 [18355842.001]
  • [Cites] Ann Oncol. 2000 Mar;11(3):263-71 [10811491.001]
  • [Cites] J Urol. 2006 Aug;176(2):703-5 [16813923.001]
  • [Cites] Pediatr Hematol Oncol. 1998 Mar-Apr;15(2):135-42 [9592840.001]
  • [Cites] Urology. 2006 Aug;68(2):402-5; discussion 405 [16904461.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):309-14 [17080332.001]
  • [Cites] J Urol. 1995 Apr;153(4):1259-61 [7869524.001]
  • (PMID = 19280171.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 19
  •  go-up   go-down


38. Agarwal PK, Palmer JS: Testicular and paratesticular neoplasms in prepubertal males. J Urol; 2006 Sep;176(3):875-81
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular and paratesticular neoplasms in prepubertal males.
  • PURPOSE: We reviewed the current diagnosis, staging and management of testicular and paratesticular neoplasms in prepubertal males.
  • MATERIALS AND METHODS: We performed a medical literature search in English using MEDLINE/PubMed that addressed testicular and/or paratesticular neoplasms in prepubertal males.
  • RESULTS: There is still a predominance of yolk sac tumors in prepubertal males, although some studies suggest that teratomas are more common but underreported due to their benign course in children.
  • A palpable, nontender mass suggests the diagnosis and prompts scrotal ultrasound and tumor markers.
  • Although treatment for most primary tumors has historically been radical inguinal orchiectomy, most benign tumors can now be managed by testis sparing surgery.
  • The addition of radiation, chemotherapy and/or retroperitoneal lymph node dissection depends on tumor stage and histological type.
  • CONCLUSIONS: Although it is rare in children, any solid scrotal mass in prepubertal males warrants evaluation for possible testicular or paratesticular neoplasm.
  • [MeSH-major] Testicular Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890643.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down






Advertisement